A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer

Conditions

Colon | Rectum

Phase II

What is the purpose of this trial?

This phase II trial studies how well savolitinib works in treating participants with MET amplified colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • Trial with
    National Cancer Institute
  • Start Date
    06/25/2019
  • End Date
    09/29/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Christina Wiess

  • Last Updated
    06/27/2019
  • Study HIC
    #2000025224